课题基金 / 基金详情

项目摘要

项目成果

Michael Pawlita的其他基金

相似基金

相关文献

中文摘要
翻译
总体目标是在临床前模型中开发艾地骨化醇(艾德-71)用于结直肠癌预防。具体而言,承包商应获得所需数量的艾德-71,确定最佳剂量和/或非钙剂剂量,对艾德-7介导的APC-min小鼠结肠癌预防进行深入评估,此外,还应确定艾德-71特异性分子靶点,以预防APC-min小鼠的肿瘤频率、发病率、多样性等。
英文摘要
The overall objective is to develop Eldecalcitol (ED-71) for colorectal cancer prevention in a preclinical model. Specifically, the Contractor shall obtain required quantities of ED-71, establish the optimal dose and/or non-calcemic dose, perform in depth assessment of ED-7-mediated colon cancer prevention in APC-min mice, in addition to, identifying ED-71 specific molecular target(s) in preventing tumor frequency, incidence, multiplicity, etc. in APC-min mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Patterns of Care/Quality of Care Study - Diagnosis Year 2012; HHSN261201300010I T
  • 批准号:
    8752581
  • 项目类别:
  • 资助金额:
    $2.23万
  • 财政年份:
    2013
  • 负责人:
    Michael Pawlita
  • 依托单位:
Surveillance, Epidemiology, and End Results (SEER) Program
  • 批准号:
    8743667
  • 项目类别:
  • 资助金额:
    $255.05万
  • 财政年份:
    2013
  • 负责人:
    Michael Pawlita
  • 依托单位:
MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas
  • 批准号:
    8762914
  • 项目类别:
  • 资助金额:
    $93.95万
  • 财政年份:
    2013
  • 负责人:
    Michael Pawlita
  • 依托单位:
Surveillance, Epidemiology, and End Results (SEER) Program
海外基金